N-acetyl-L-Cysteine amide
(Synonyms: N-乙酰-L-胱氨酸) 目录号 : GC44301
N-乙酰-L-半胱氨酸酰胺 (NACA) 是一种新型抗氧化剂，它是 N-乙酰半胱氨酸 (NAC) 的酰胺形式，因为它可渗透细胞膜和线粒体膜 . N-乙酰半胱氨酸酰胺可透过细胞膜和线粒体膜，穿过血脑屏障，具有比NAC更高的自由基清除能力、金属螯合活性和还原能力。
Cas No.:38520-57-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
| Cell experiment [1]: | |
|
Cell lines |
PC12 cells |
|
Preparation Method |
PC12 cells were plated at a density of 25 × 103 cells/well in a 24-well collagen-coated plate for morphological assessment. The plate was divided into five groups in triplicate: (1) control: no glutamate, no N-acetyl-L-Cysteine amide (NACA); (2) Nerve growth factor (NGF) control: NGF (100 ng/ml), no glutamate, no NACA; (3) NACA only: NGF (100 ng/ml), no glutamate, NACA (750 µM); (4) glutamate only: NGF (100 ng/ml), glutamate (10 mM), no NACA; and (5) Glu + NACA: NGF (100 ng/ml), glutamate (10 mM), NACA (750 µM). All wells received 100 ng/ml NGF every other day, except Group I. After 1 week, cells were treated or not (control) with 10 mM glutamate, with or without NACA, for 24 h. Twenty-four hours later, the cells were fixed with 0.5% (v/v) glutaraldehyde in PBS and micropictures were taken. |
|
Reaction Conditions |
750 µM for 24 h |
|
Applications |
The addition of N-acetyl-L-Cysteine amide protected the PC12 cells from glutamate toxicity by slightly decreasing the bleb formation on neurites. |
| Animal experiment [2]: | |
|
Animal models |
Adult male Sprague-Dawley rats |
|
Preparation Method |
In order to access tissue sparing following Traumatic brain injury (TBI), rats were randomly divided into three groups: (I.) N-acetyl-L-Cysteine amide (NACA) loaded pump (18.5 mg/kg/hr) and a single 150 mg/kg bolus intraperitoneal (IP) injection of NACA given (30 min post-injury) (II.) N-acetylcysteine (NAC) (18.5 mg/kg/hr) loaded pump and a single 150 mg/kg bolus injection of NAC given IP (30 min post-injury) (III.) Vehicle loaded pump and single vehicle bolus injection given IP (30 min post-injury). Following random distribution of all animals into one of the three previous groups, experimenters were blinded to treatment group. |
|
Dosage form |
loaded pump (18.5 mg/kg/hr) and a single 150 mg/kg, IP |
|
Applications |
N-acetyl-L-Cysteine amide treatment improved cognitive outcome following TBI as demonstrated by the significant improvements in distance traveled to goal as measured using the Morris Water Maze task. |
|
References: [1]: Penugonda S, Mare S, Goldstein G, et al. Effects of N-acetylcysteine amide (NACA), a novel thiol antioxidant against glutamate-induced cytotoxicity in neuronal cell line PC12[J]. Brain research, 2005, 1056(2): 132-138. | |
N-acetyl-L-Cysteine amide (NACA) is a novel antioxidant, the amide form of N-acetylcysteine (NAC), due to its permeability through both cellular and mitochondrial membranes [1]. N-acetylcysteine amide permeates cellular and mitochondrial membranes, crosses the blood-brain barrier [1,2] and has higher radical scavenging ability, metal chelating activity and reducing power than NAC [3].
N-acetyl-L-Cysteine amide protects neurons and dopaminergic cells from oxidative stress in tissue cultures and lipid peroxidation in neuronal cell lines [4,5]. N-acetyl-L-Cysteine amide (750 µM) protected the PC12 cells from glutamate toxicity by slightly decreasing the bleb formation on neurites, and increased the PC12 cell GSH level [5]. N-acetyl-L-Cysteine amide protected PC12 cells against glutamate cytotoxicity by decreasing the glutamate-induced ROS accumulation [5]. N-acetylcysteine amide (1 mM) prevents METH-induced oxidative stress in human brain microvascular endothelial (HBMVEC) cells [6].
In moderate TBI, N-acetyl-L-Cysteine amide treatment improves mitochondrial bioenergetics, cognitive function, cortical tissue sparing and reduces lipid peroxidation product 4-hydroxynonenal compared to NAC or vehicle treated rats [7]. In acute spinal cord injury, N-acetyl-L-Cysteine amide (150 or 300 mg/kg/day) treatment improves mitochondrial bioenergetics, maintains mitochondrial glutathione and improves tissue sparing and hind limb function [8].
References:
[1]. Grinberg L, Fibach E, Amer J, et al. N-acetylcysteine amide, a novel cell-permeating thiol, restores cellular glutathione and protects human red blood cells from oxidative stress[J]. Free Radical Biology and Medicine, 2005, 38(1): 136-145.
[2]. Offen D, Gilgun?\Sherki Y, Barhum Y, et al. A low molecular weight copper chelator crosses the blood-brain barrier and attenuates experimental autoimmune encephalomyelitis[J]. Journal of neurochemistry, 2004, 89(5): 1241-1251.
[3]. Ates B, Abraham L, Ercal N. Antioxidant and free radical scavenging properties of N-acetylcysteine amide (NACA) and comparison with N-acetylcysteine (NAC)[J]. Free radical research, 2008, 42(4): 372-377.
[4]. Bahat?\Stroomza M, Gilgun?\Sherki Y, Offen D, et al. A novel thiol antioxidant that crosses the blood brain barrier protects dopaminergic neurons in experimental models of Parkinson's disease[J]. European Journal of Neuroscience, 2005, 21(3): 637-646.
[5]. Penugonda S, Mare S, Goldstein G, et al. Effects of N-acetylcysteine amide (NACA), a novel thiol antioxidant against glutamate-induced cytotoxicity in neuronal cell line PC12[J]. Brain research, 2005, 1056(2): 132-138.
[6]. Zhang X, Banerjee A, Banks W A, et al. N-Acetylcysteine amide protects against methamphetamine-induced oxidative stress and neurotoxicity in immortalized human brain endothelial cells[J]. Brain research, 2009, 1275: 87-95.
[7]. Pandya J D, Readnower R D, Patel S P, et al. N-acetylcysteine amide confers neuroprotection, improves bioenergetics and behavioral outcome following TBI[J]. Experimental neurology, 2014, 257: 106-113.
[8]. Patel S P, Sullivan P G, Pandya J D, et al. N-acetylcysteine amide preserves mitochondrial bioenergetics and improves functional recovery following spinal trauma[J]. Experimental neurology, 2014, 257: 95-105.
N-乙酰-L-半胱氨酸酰胺 (NACA) 是一种新型抗氧化剂,它是 N-乙酰半胱氨酸 (NAC) 的酰胺形式,因为它可渗透细胞膜和线粒体膜[1] . N-乙酰半胱氨酸酰胺可透过细胞膜和线粒体膜,穿过血脑屏障[1,2],具有比NAC更高的自由基清除能力、金属螯合活性和还原能力[3]。
N-乙酰-L-半胱氨酸酰胺保护神经元和多巴胺能细胞免受组织培养物中的氧化应激和神经元细胞系中的脂质过氧化 [4,5]。 N-乙酰基-L-半胱氨酸酰胺 (750 µM) 通过略微减少神经突上的气泡形成来保护 PC12 细胞免受谷氨酸毒性,并增加 PC12 细胞 GSH 水平 [5]。 N-乙酰-L-半胱氨酸酰胺通过减少谷氨酸诱导的 ROS 积累来保护 PC12 细胞免受谷氨酸细胞毒性 [5]。 N-乙酰半胱氨酸酰胺 (1 mM) 可防止 METH 诱导的人脑微血管内皮 (HBMVEC) 细胞氧化应激 [6]。
在中度 TBI 中,N-乙酰-L-半胱氨酸酰胺治疗可改善线粒体生物能量学、认知功能、皮质组织保护和减少脂质过氧化产物 4-hydroxynonenal 与 NAC 或载体处理的大鼠相比 [7]。在急性脊髓损伤中,N-乙酰基-L-半胱氨酸酰胺（150 或 300 mg/kg/天）治疗可改善线粒体生物能量学,维持线粒体谷胱甘肽并改善组织保护和后肢功能[8]。
| Cas No. | 38520-57-9 | SDF | |
| 别名 | N-乙酰-L-胱氨酸 | ||
| Canonical SMILES | SC[C@H](NC(C)=O)C(N)=O | ||
| 分子式 | C5H10N2O2S | 分子量 | 162.2 |
| 溶解度 | DMF: 50 mg/mL,DMSO: 50 mg/mL,Ethanol: 50 mg/mL,PBS (pH 7.2): 30 mg/mL | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 6.1652 mL | 30.8261 mL | 61.6523 mL |
| 5 mM | 1.233 mL | 6.1652 mL | 12.3305 mL |
| 10 mM | 0.6165 mL | 3.0826 mL | 6.1652 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Acetaminophen Poisoning
Acetaminophen is a common medication taken in deliberate self-poisoning and unintentional overdose. It is the commonest cause of severe acute liver injury in Western countries. The optimal management of most acetaminophen poisonings is usually straightforward. Patients who present early should be offered activated charcoal and those at risk of acute liver injury should receive acetylcysteine. This approach ensures survival in most. The acetaminophen nomogram is used to assess the need for treatment in acute immediate-release overdoses with a known time of ingestion. However, scenarios that require different management pathways include modified-release, large/massive, and repeated supratherapeutic ingestions.
Paracetamol
Paracetamol is an analgesic and antipyretic agent which was first marketed for use as a drug in the U.K. in 1956. It has since become popular with the medical profession and the general public as an alternative to aspirin.
Acetaminophen hepatotoxicity
Acetaminophen is a commonly used antipyretic and analgesic agent. It is safe when taken at therapeutic doses; however, overdose can lead to serious and even fatal hepatotoxicity. The initial metabolic and biochemical events leading to toxicity have been well described, but the precise mechanism of cell injury and death is unknown. Prompt recognition of overdose, aggressive management, and administration of N-acetylcysteine can minimize hepatotoxicity and prevent liver failure and death. Liver transplantation can be lifesaving for those who develop acute liver failure.
Acetaminophen from liver to brain: New insights into drug pharmacological action and toxicity
Acetaminophen (APAP) is a well-known analgesic and antipyretic drug. It is considered to be safe when administered within its therapeutic range, but in cases of acute intoxication, hepatotoxicity can occur. APAP overdose is the leading cause of acute liver failure in the northern hemisphere. Historically, studies on APAP toxicity have been focused on liver, with alterations in brain function attributed to secondary effects of acute liver failure. However, in the last decade the pharmacological mechanism of APAP as a cannabinoid system modulator has been documented and some articles have reported "in situ" toxicity by APAP in brain tissue at high doses. Paradoxically, low doses of APAP have been reported to produce the opposite, neuroprotective effects. In this paper we present a comprehensive, up-to-date overview of hepatic toxicity as well as a thorough review of both toxic and beneficial effects of APAP in brain.
What is the most appropriate dose of N-acetylcysteine after massive acetaminophen overdose?
While the traditional intravenous N-acetylcysteine (NAC) dosing regimen works well for the vast majority of acetaminophen overdoses, there may be cases of massive overdose where additional NAC may be necessary. Recent evidence suggests that patients with acetaminophen concentrations above the "300-line" develop hepatotoxicity at a higher rate than those below the 300-line, suggesting that an increase of dose may be beneficial at this cut-off. Additional clinical data suggest a further increase in doses at the 450-line and 600-lines. I propose a strategy for step-wise increases in NAC dosing in response to high acetaminophen concentrations at the 300-, 450-, and 600-lines after acute massive acetaminophen overdoses.